The Drug-Induced Respiratory Disease Website and App
Frequency - Incidence
Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases
Evidence level/grade
Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic
ARDS and the hemolytic-uremic syndrome (HUS)
Publications
Moya-Horno I, Querol Niñerola R, Bonfill Abella T, Dalmau Pórtulas E, Gallardo-Díaz E, Saigí Grau E, Pericay Pijaume C
Haemolytic uraemic syndrome associated with gemcitabine.
Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico. 2010;12(5):381-3
Desramé J, Duvic C, Bredin C, Béchade D, Artru P, Brézault C, Defuentes G, Poirier JM, Dourthe LM, Coutant G, Chaussade S, de Gramont A, Algayres JP
[Hemolytic uremic syndrome as a complication of gemcitabine treatment: report of six cases and review of the literature].
La Revue de medecine interne. 2005;26(3):179-88
Fatal pulmonary toxicity in a patient treated with gefitinib for non-small cell lung cancer after previous hemolytic-uremic syndrome due to gemcitabine.
Anti-cancer drugs. 2003;14(8):665-8
Gemcitabine-associated hemolytic-uremic syndrome.
American journal of kidney diseases : the official journal of the National Kidney Foundation. 2002;40(4):E16
Gemcitabine-associated diffuse alveolar hemorrhage.
Intensive care medicine. 2001;27(9):1554
A review of hemolytic uremic syndrome in patients treated with gemcitabine therapy.
Cancer. 1999;85(9):2023-32